Business Wire

Merz Aesthetics ® Announces Salma Hayek Pinault as First-Ever Global Brand Ambassador for Ultherapy PRIME, the Next Generation Platform for Nonsurgical Skin Lifting and Tightening Treatments

Share

Merz Aesthetics®, the world’s largest dedicated medical aesthetics business, is proud to announce world-renowned actress, director and producer, Salma Hayek Pinault, as the first-ever global brand ambassador for Ultherapy PRIME.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250409655489/en/

Redefining the future in medical aesthetics, Ultherapy PRIME is an advanced micro-focused ultrasound platform for personalized, non-invasive skin lifting and tightening.1,2 It is intended to lift and sculpt the skin of the upper face, lower face, neck and décolleté.1 It takes just one session, has no downtime, and delivers results that can last up to a year or more.1-3

With her unwavering commitment to authenticity, Salma Hayek Pinault trusts Ultherapy PRIME for a personalized, natural-looking lift, with results that can last up to a year or more .1-3 This collaboration reflects a shared belief in empowering individuals to look and feel their best to fuel confidence worldwide.

Salma Hayek Pinault is a highly acclaimed, Academy Award-nominated actress and Emmy-winning director, also celebrated for her work as a producer. She passionately advocates for causes that align with her core values and beliefs and has long supported several leading nonprofit organizations. As a strong advocate for authentic self-expression and looking great at any age, she encourages others to embrace treatments that enhance their natural features.

“Self-care is essential. Years on screen have taught me to embrace my journey and seek treatments that enhance my natural beauty,” said Salma Hayek Pinault. “Ultherapy PRIME boosts my production of collagen and elastin exactly where I need it*, giving me a long-lasting**, natural-looking lift. It's noninvasive, takes only one session, and has zero downtime. It is the future of beauty, and that’s why I can't stop talking about it."1-3,6

The Ultherapy PRIME platform is the evolution of Ultherapy® which has been recognized as the Gold Standard in non-invasive skin lifting and tightening.2 Built on Ultherapy®’s legacy of proven, natural-looking results, Ultherapy PRIMEredefines the future of nonsurgical skin lifting and tightening by uniquely combining an advanced micro-focused ultrasound platform with vivid real-time imaging.1 These advancements promote a safer and more effective, personalized lift that can last up to a year or more, paired with younger-looking skin.1-5

Since its September 2024 launch, Ultherapy PRIME has already been cleared in over 80% of our targeted markets, with more approvals expected in 2025.***

"We are proud and excited about the recent launch of Ultherapy PRIME, our next-generation platform for non-invasive skin lifting and tightening and a testament to our unwavering commitment to delivering meaningful innovations to our customers," said Bob Rhatigan, CEO of Merz Aesthetics®. "As we continue to expand the global footprint of this launch, we are thrilled to collaborate with Salma Hayek Pinault as the first-ever global brand ambassador for Ultherapy PRIME. At Merz Aesthetics® we empower individuals to embrace their unique beauty with confidence, and our collaboration with Salma Hayek Pinault compellingly embodies this purpose.”

To learn more and find a provider near you, visit Ultherapy.com. Follow @Ultherapy on Instagram for the latest news from Ultherapy PRIME and Hayek Pinault.

About Merz Aesthetics®

Merz Aesthetics® is a medical aesthetics business with a long history of empowering health care professionals, patients, and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves – however they define it. Clinically proven, its product portfolio includes injectables and devices designed to meet each patient’s needs Being family owned for more than 115 years, Merz Aesthetics® is known for building unique connections with customers who feel like family. Merz Aesthetics®’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.

About Ultherapy®

The noninvasive Ultherapy® procedure is intended for dermatological sculpting and lifting of the dermis on the upper face, lower face, neck and décolleté. The most common side effects reported in clinical trials were redness, swelling, pain and transient nerve effects. Reported adverse events from post-marketing surveillance are available in the Instructions for Use (IFU). Please see the IFU for product information.

* The exact skin depth targeting occurs due to real-time visualization

**lasts up to a year or more

***Ultherapy PRIME is currently unavailable in China, India, Azerbaijan, Russia, Costa Rica, Dominican Republic, Guatemala, Mexico, Peru, Uruguay, Iraq, Israel, Jordan, Lebanon

References:

  1. Ulthera® Instructions for Use.
  2. Fabi SG, Joseph J, Sevi J, Green JB, Peterson JD. Optimizing patient outcomes by customizing treatment with microfocused ultrasound with visualization: gold standard consensus guidelines from an expert panel. J Drugs Dermatol. 2019;18(5):426-432.
  3. Werschler WP, Werschler PS. Longterm efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;9(2):27-33.
  4. Pavicic T, Ballard JR, Bykovskaya T, et al. Microfocused ultrasound with visualization: consensus on safety and review of energy-based devices. J Cosmet Dermatol. 2022;21(2):636-647.
  5. Goldie K, Kerscher M, Fabi SG, Hirano C, Landau M, Lim TS, Woolery-Lloyd H, Mariwalla K, Park JY, Yutskovskaya Y. Skin Quality - A Holistic 360° View: Consensus Results. Clin Cosmet Investig Dermatol. 2021 Jun 14;14:643-654. doi: 10.2147/CCID.S309374. PMID: 34163203; PMCID: PMC8214518.
  6. Marquardt K, Hartmann C, Wegener F, Park JY, Halbert D, Hsu S, Hengl T. Microfocused Ultrasound With Visualization Induces Remodeling of Collagen and Elastin Within the Skin. J Cosmet Dermatol. 2025 Jan;24(1):e16638

© 2025 Ulthera, Inc. All Rights Reserved. MERZ AESTHETICS® is a trademark and/or registered trademark of Merz Pharma GmbH & Co. KGaA in the U.S. and/or certain other countries. ULTHERA, ULTHERAPY, and ULTHERAPY PRIME are trademarks and/or registered trademarks of Ulthera, Inc. in the U.S. and/or certain other countries.

Various features of the ULTHERA® System are covered by U.S. patents identified at https://merzaesthetics.com/patents/. Other U.S. and international patents to which Ulthera, Inc. has rights are issued, published, or pending.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250409655489/en/

Contacts

Media Contact
Merz Aesthetics®
Global Corporate Communications
6501 Six Forks Road, Raleigh NC 27615
919-302-3296
media@merz.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcts.businesswi
re.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dmailto%253A%252520media%2540merz.com%2
6esheet%3D54233560%26lan%3Den-US%26anchor%3Dmedia%2540merz.com%26index%3D3%26md5
%3D3235cfec4a5c30f18dfe762506c5dbc1&esheet=54233560&newsitemid=20250409655489&la
n=en-US&anchor=media%40merz.com&index=5&md5=1e3beed262b8f35333c21d285a109647

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in

You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release

Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc

CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release

Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale

Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release

In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha

FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release

Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye